{"url_path":"/sec/ivf/10-k/2026/item-5","section_key":"item-5","section_title":"Item 5 Market for Registrant**’**s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities**","topic":"sec","document":{"doc_type":"10-K","doc_date":"2026-06-02","source_url":"https://www.sec.gov/Archives/edgar/data/1417926/0001493152-26-026775-index.html","accession_number":"0001493152-26-026775","cik":"0001417926","ticker":"IVF","issuer_name":"INVO Fertility, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1417926/0001493152-26-026775-index.html","primary_entity_key":"0001417926","primary_entity_name":"INVO Fertility, Inc."},"word_count":190,"has_tables":true,"body_markdown":"**Item\n5. Market for Registrant**’**s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities** \n\n \n\n**Market\nInformation**\n\n \n\nTrading\nof our shares of our common stock is on the Nasdaq Capital Market under the symbol “IVF.”\n\n \n\nAs of June 2, 2026, there were 1,786,035 shares\nof our common stock outstanding.\n\n \n\nInformation\nrequired with respect to equity compensation plans in this Item 5 is included in Item 11 on page 92 of this report on Form 10-K.\n\n \n\n**Stockholders**\n\n \n\nAs\nof March 31, 2026, there were approximately 231 stockholders of record of our common stock. However, we estimate that we have a significantly\ngreater number of beneficial holders of our common stock because a number of shares are held of record by broker-dealers for their customers\nin street name.\n\n \n\n**Dividend\nPolicy**\n\n \n\nWe\nhave never declared or paid dividends on our common stock. We intend to retain future earnings (if any) to fund the development and\ngrowth of our business, rather than to pay them as dividends, for the foreseeable future.\n\n \n\n**Recent\nSales of Unregistered Securities**\n\n \n\nNone.\n\n \n\n**Purchase\nof Equity Securities**\n\n \n\nNo\nrepurchase of equity securities were made during the 2025 fiscal year."}